Future University is one of most promising private universities in Egypt. Through excellence in teaching, research and service, Future University strives to provide a comprehensive, high-quality education that prepares our graduates to be future leaders.
mainLogo
90th Street
New Cairo
Egypt

mina ibrahim tadros

Basic information

Name : mina ibrahim tadros
Title: Assistant Professor of Pharmaceutics and Industrial Pharmacy
Google Schoolar Link:
Personal Info: Dr. Mina Ibrahim, Associate Professor of Pharmaceutics and Industrial Pharmacy, Pharmaceutics and Pharmaceutical Technology Department. He got his master and Doctoral degree from Cairo University. View More...

Education

Certificate Major University Year
PhD Faculty of Pharmacy Cairo University 2006
Masters Faculty of Pharmacy Cairo University 2002
Bachelor Faculty of Pharmacy Cairo University 1998

Teaching Experience

Name of Organization Position From Date To Date
Department of Pharmaceutics and Industrial Pharmacy, Cairo University Associate professor 28/03/2012 17/04/2014
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University Lecturer 04/06/2006 27/03/2012
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University Assistant Lecturer 05/01/2003 03/06/2006
Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University Teaching Assistant 21/10/1998 04/01/2003

Researches /Publications

Colon-targeted celecoxib-loaded Eudragit(®) S100-coated poly-ϵ-caprolactone microparticles: preparation, characterization and in vivo evaluation in rats. - 01/0

Mina Ibrahim Tadros Ayyad

01/01/2011

Context: Celecoxib suffers from low and variable bioavailability following oral administration of solutions or capsules. Recent studies proved that chemoprevention of colorectal cancer is possible with celecoxib. Objective: This work aims to tailor colon-targeted celecoxib-loaded microparticles using time-dependant and pH-dependant coats. Estimation of drug pharmacokinetics following oral administration to fasted rats was another goal. Methods: A 23 factorial design was adopted to develop poly-ε-caprolactone (PCL) celecoxib-loaded microparticles (F1 – F8). To minimize drug-percentages released before colon, another coat of Eudragit® S100 was applied. In vitro characterization of microparticles involved topography, determination of particle size and entrapment efficiency (EE %). Time for 50% drug release (t50%) and drug-percentages released after 2 hours (Q2h) and 4 hours (Q4h) were statistically compared. Estimation of drug pharmacokinetics following oral administration of double-coat microparticles (F10) was studied in rats. Results: PCL-single-coat microparticles were spherical, discrete with a size range of 60.66±4.21 – 277.20±6.10 μm. Direct correlations were observed between surfactant concentration and EE%, Q2h and Q4h. The PCL M.wt. and drug: PCL ratio had positive influences on EE% and negative impacts on Q2h and Q4h. When compared to the best achieved PCL-single-coat microparticles (F2), the double-coat microparticles (F10) showed satisfactory drug protection; Q2h and Q4h were significantly (P < 0.01) decreased from 31.84±1.98% and 54.72±2.10% to 15.92±1.78% and 26.93±2.76%, respectively. When compared to celecoxib powder, F10 microparticles enhanced the bioavailability and extended the duration of drug-plasma concentration in rats. Conclusion: The developed double-coat microparticles could be considered as a promising celecoxib extended-release colon-targeting system.

Download PDF
Transdermal delivery of an anti-cancer drug via w/o emulsions based on alkyl polyglycosides and lecithin: design, characterization and in vivo evaluation of the possible irritation potential in rats - 01/0

Mina Ibrahim Tadros Ayyad

01/01/2011

The purpose of this work was to develop w/o emulsions that could be safely used to promote transdermal delivery of 5-fluorouracil (5-FU). Two pseudo-ternary phase diagrams comprising oleoyl-macrogol glycerides, water and a surfactant/co-surfactant (S/CoS) mixture of lecithin, ethanol and either coco glucoside or decyl glucoside were investigated for their potential to develop promising 5-FU emulsions. Six systems were selected and subjected to thermodynamic stability tests; heat – cool cycles, centrifugation and finally freeze – thaw cycles. All systems passed the challenges and were characterized for transmission electron microscopy, droplet size, rheological behavior, pH and transdermal permeation through newly born mice skin in Franz diffusion cells. The systems had spherical droplets ranging in diameter from 1.81 to 2.97 μm, pH values ranging from 7.50 to 8.49 and possessed Newtonian flow. A significant (P < 0.05) increase in 5-FU permeability parameters as steady-state flux, permeability coefficient was achieved with formula B5 comprising water (5% w/w), S/CoS mixture of lecithin: ethanol: decyl glucoside (14.67: 12.15: 18.18% w/w, respectively) and oleoyl-macrogol glycerides (50% w/w). When applied to shaved rat skin, this system was well tolerated with only moderate skin irritation that was recovered within 12 h. Indeed, minor histopathologic changes were observed after 5-days treatment. Further studies should be carried out, in the future, to investigate the potentiality of this promising system to promote transdermal delivery of 5-FU through human skin.

Download PDF
Development and in vitro/in vivo evaluation of etodolac controlled porosity osmotic pump tablets - 01/0

Mina Ibrahim Tadros Ayyad

01/01/2011

The aim of the current work was the design and evaluation of etodolac controlled porosity osmotic pump (CPOP) tablets exhibiting zero order release kinetics. Variables influencing the design of (I) core tablets viz., (i) osmogent type (sodium chloride, potassium chloride, mannitol and fructose) and (ii) drug: osmogent ratio (1: 0.25, 1: 0.50 and 1: 0.75)] and (II) CPOP tablets viz., (i) coating solution composition, (ii) weight gain percentage (1 – 5%, w/w) and (iii) pore former concentration (5, 10 and 20%, v/v)] were investigated. Statistical analysis and kinetic modeling of drug release data were estimated. Fructose-containing core tablets showed significantly (P < 0.05) more retarded drug release rates. An inverse correlation was observed between drug: fructose ratio and drug release rate. Coating of the optimum core tablets (F4) with a mixture of cellulose acetate solution (3 %, w/v), diethyl phthalate and polyethylene glycol 400 (85: 10: 5 v/v, respectively) till a 4% w/w weight gain enabled zero order-sustained drug delivery over 24 h. SEM micrographs of coating membrane confirmed pore formation upon contact with dissolution medium. When compared to the commercial immediate release Napilac® capsules, the optimum CPOP tablets (F4 - 34) provided enhanced bioavailability, extended duration of effective etodolac plasma concentration with minimum expected potential for side effects in healthy volunteers.

Download PDF
Colon-targeted celecoxib-loaded Eudragit(®) S100-coated poly-ϵ-caprolactone microparticles: preparation, characterization and in vivo evaluation in rats. - 01/0

Mina Ibrahim Tadros Ayyad

01/01/2011

Context: Celecoxib suffers from low and variable bioavailability following oral administration of solutions or capsules. Recent studies proved that chemoprevention of colorectal cancer is possible with celecoxib. Objective: This work aims to tailor colon-targeted celecoxib-loaded microparticles using time-dependant and pH-dependant coats. Estimation of drug pharmacokinetics following oral administration to fasted rats was another goal. Methods: A 23 factorial design was adopted to develop poly-ε-caprolactone (PCL) celecoxib-loaded microparticles (F1 – F8). To minimize drug-percentages released before colon, another coat of Eudragit® S100 was applied. In vitro characterization of microparticles involved topography, determination of particle size and entrapment efficiency (EE %). Time for 50% drug release (t50%) and drug-percentages released after 2 hours (Q2h) and 4 hours (Q4h) were statistically compared. Estimation of drug pharmacokinetics following oral administration of double-coat microparticles (F10) was studied in rats. Results: PCL-single-coat microparticles were spherical, discrete with a size range of 60.66±4.21 – 277.20±6.10 μm. Direct correlations were observed between surfactant concentration and EE%, Q2h and Q4h. The PCL M.wt. and drug: PCL ratio had positive influences on EE% and negative impacts on Q2h and Q4h. When compared to the best achieved PCL-single-coat microparticles (F2), the double-coat microparticles (F10) showed satisfactory drug protection; Q2h and Q4h were significantly (P < 0.01) decreased from 31.84±1.98% and 54.72±2.10% to 15.92±1.78% and 26.93±2.76%, respectively. When compared to celecoxib powder, F10 microparticles enhanced the bioavailability and extended the duration of drug-plasma concentration in rats. Conclusion: The developed double-coat microparticles could be considered as a promising celecoxib extended-release colon-targeting system.

Download PDF
Development and in vitro/in vivo evaluation of etodolac controlled porosity osmotic pump tablets - 01/0

Mina Ibrahim Tadros Ayyad

01/01/2011

The aim of the current work was the design and evaluation of etodolac controlled porosity osmotic pump (CPOP) tablets exhibiting zero order release kinetics. Variables influencing the design of (I) core tablets viz., (i) osmogent type (sodium chloride, potassium chloride, mannitol and fructose) and (ii) drug: osmogent ratio (1: 0.25, 1: 0.50 and 1: 0.75)] and (II) CPOP tablets viz., (i) coating solution composition, (ii) weight gain percentage (1 – 5%, w/w) and (iii) pore former concentration (5, 10 and 20%, v/v)] were investigated. Statistical analysis and kinetic modeling of drug release data were estimated. Fructose-containing core tablets showed significantly (P < 0.05) more retarded drug release rates. An inverse correlation was observed between drug: fructose ratio and drug release rate. Coating of the optimum core tablets (F4) with a mixture of cellulose acetate solution (3 %, w/v), diethyl phthalate and polyethylene glycol 400 (85: 10: 5 v/v, respectively) till a 4% w/w weight gain enabled zero order-sustained drug delivery over 24 h. SEM micrographs of coating membrane confirmed pore formation upon contact with dissolution medium. When compared to the commercial immediate release Napilac® capsules, the optimum CPOP tablets (F4 - 34) provided enhanced bioavailability, extended duration of effective etodolac plasma concentration with minimum expected potential for side effects in healthy volunteers.

Download PDF

Awards

Award Donor Date
International publication award Cairo University 2011
Patent no. 24388 for "A method for the preparation of nebulizable micronized niosomes of cromolyn sodium using non ionic surfactants". The Academy of scientific research and technology, Egyptian Patent office, Egypt. 2006
Patent no. 23170 for "A method for the production of biodegradable chitosan - gelatin sponges containing tramadol hydrochloride". The Academy of scientific research and technology, Egyptian Patent office, Egypt. 2002

Follow us on

Visit the Faculty

ADS